{"id":"https://openalex.org/W2754580435","doi":"https://doi.org/10.1161/circulationaha.117.030484","title":"Inflammation and Atherosclerosis: The End of a Controversy","display_name":"Inflammation and Atherosclerosis: The End of a Controversy","alternate_titles":[],"publication_year":2017,"publication_date":"2017-09-16","ids":{"openalex":"https://openalex.org/W2754580435","doi":"https://doi.org/10.1161/circulationaha.117.030484","mag":"2754580435","pmid":"https://pubmed.ncbi.nlm.nih.gov/28916641"},"language":"en","primary_location":{"id":"doi:10.1161/circulationaha.117.030484","doi":"https://doi.org/10.1161/circulationaha.117.030484","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circulationaha.117.030484","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2754580435"],"child_works_count":0,"type":"editorial","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004855576","display_name":"G\u00f6ran K. Hansson","orcid":"https://orcid.org/0000-0003-4148-5190","observed_orcids":["https://orcid.org/0000-0003-4148-5190"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]}],"countries":["SE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"G\u00f6ran K. Hansson","raw_affiliation_strings":["Department of Medicine, Solna and Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Solna and Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden","institution_ids":["https://openalex.org/I1335113835","https://openalex.org/I28166907"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5004855576"],"corresponding_institution_ids":["https://openalex.org/I1335113835","https://openalex.org/I28166907"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":161,"reviewed_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"20","first_page":"1875","last_page":"1877"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":0.9550999999046326,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":0.9550999999046326,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.040300000458955765,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11078","display_name":"Inflammasome and immune disorders","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.9580000042915344},{"id":"https://openalex.org/keywords/coronary-artery-disease","display_name":"coronary artery disease","score":0.8989999890327454},{"id":"https://openalex.org/keywords/cantos-trial","display_name":"CANTOS trial","score":0.9330000281333923},{"id":"https://openalex.org/keywords/canakinumab","display_name":"canakinumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/interleukin-1beta","display_name":"IL-1\u03b2","score":0.8610000014305115},{"id":"https://openalex.org/keywords/high-sensitivity-c-reactive-protein","display_name":"high-sensitivity C-reactive protein","score":0.9039999842643738},{"id":"https://openalex.org/keywords/cardiovascular-disease-prevention","display_name":"cardiovascular disease prevention","score":0.7379999756813049},{"id":"https://openalex.org/keywords/residual-cardiovascular-risk","display_name":"residual cardiovascular risk","score":0.5789999961853027},{"id":"https://openalex.org/keywords/statin-therapy","display_name":"statin therapy","score":0.7440000176429749},{"id":"https://openalex.org/keywords/anti-inflammatory-therapy","display_name":"anti-inflammatory therapy","score":0.7689999938011169},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.8240000009536743},{"id":"https://openalex.org/keywords/secondary-prevention","display_name":"secondary prevention","score":0.5080000162124634},{"id":"https://openalex.org/keywords/cardiovascular-mortality","display_name":"cardiovascular mortality","score":0.3610000014305115},{"id":"https://openalex.org/keywords/myocardial-infarction-recurrence","display_name":"myocardial infarction recurrence","score":0.6140000224113464},{"id":"https://openalex.org/keywords/ischemic-stroke","display_name":"ischemic stroke","score":0.5929999947547913},{"id":"https://openalex.org/keywords/ischemic-gangrene","display_name":"ischemic gangrene","score":0.6790000200271606}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.926479697227478},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.7258331179618835},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27872568368911743}],"mesh":[{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003324","descriptor_name":"Coronary Artery Disease","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D003324","descriptor_name":"Coronary Artery Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003324","descriptor_name":"Coronary Artery Disease","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D003324","descriptor_name":"Coronary Artery Disease","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018836","descriptor_name":"Inflammation Mediators","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018836","descriptor_name":"Inflammation Mediators","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D053583","descriptor_name":"Interleukin-1beta","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D053583","descriptor_name":"Interleukin-1beta","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D055502","descriptor_name":"Secondary Prevention","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1161/circulationaha.117.030484","doi":"https://doi.org/10.1161/circulationaha.117.030484","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circulationaha.117.030484","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},{"id":"pmid:28916641","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28916641","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W2033896075","https://openalex.org/W2035192731","https://openalex.org/W2596179513","https://openalex.org/W2748400555","https://openalex.org/W2750254726"],"related_works":["https://openalex.org/W2804409796","https://openalex.org/W2888682398","https://openalex.org/W2964952983","https://openalex.org/W2783862688","https://openalex.org/W2955824846","https://openalex.org/W3043785095","https://openalex.org/W2793524354","https://openalex.org/W3005891014","https://openalex.org/W2777352038","https://openalex.org/W4378234224"],"abstract_inverted_index":{"oes":[0],"inflammation":[1,298],"matter":[2],"in":[3,11,43,71,137,143,151,190,209,227,285,355,367,414,420],"coronary":[4],"artery":[5],"disease?Is":[6],"it":[7,235,377],"a":[8,45,62,83,113,141,163,203,272,279,335,362,433,442],"driving":[9],"force":[10],"atherosclerosis":[12],"or":[13,349,401],"merely":[14],"an":[15,102],"epiphenomenon?Is":[16],"there":[17],"space":[18],"for":[19,65,92,101,112,202,260,315],"novel":[20],"therapies":[21],"besides":[22],"those":[23],"targeting":[24,120],"cholesterol?The":[25],"CANTOS":[26,269],"trial":[27,59,284],"(Canakinumab":[28],"Anti-inflammatory":[29],"Thrombosis":[30],"Outcomes":[31],"Study),":[32],"which":[33],"was":[34,236,393],"presented":[35],"at":[36,345],"the":[37,55,68,133,144,155,158,179,207,210,268,275,297,310,340,391,394,415,421],"European":[38],"Society":[39],"of":[40,57,74,85,105,116,132,146,154,166,181,206,214,263,267,274,296,309,365,390,397,441],"Cardiology":[41],"meeting":[42],"Barcelona":[44],"few":[46],"weeks":[47],"ago,":[48],"provides":[49],"answers":[50],"to":[51,172,188,339,418,432],"these":[52],"important":[53],"questions.Indeed,":[54],"results":[56,266],"this":[58,167,405],"open":[60],"up":[61],"new":[63],"avenue":[64],"cardiovascular":[66,127,184,228,264,402],"prevention.Atherosclerosis,":[67],"underlying":[69],"pathology":[70],"most":[72],"cases":[73],"myocardial":[75,147,247,291,398],"infarction,":[76,399],"ischemic":[77,80],"stroke,":[78,400],"and":[79,94,107,124,162,197,253,293,321,360,438],"gangrene,":[81],"is":[82,278,351],"disease":[84],"complex":[86],"genesis":[87],"that":[88,238,332],"has":[89,129,198],"remained":[90],"controversial":[91],"decades.Clinical":[93],"experimental":[95],"studies":[96],"have":[97,139,241],"provided":[98],"unequivocal":[99],"evidence":[100],"etiologic":[103],"role":[104,115],"cholesterol":[106,196],"also":[108,240],"offered":[109],"strong":[110],"support":[111,233],"pathogenic":[114],"inflammation.":[117],"1":[118],"By":[119],"cholesterol,":[121],"blood":[122],"pressure,":[123],"cigarette":[125],"smoking,":[126],"prevention":[128,283],"become":[130,199],"one":[131],"great":[134],"success":[135,213],"stories":[136],"medicine.We":[138],"witnessed":[140],"reduction":[142,436],"incidence":[145,180],"infarction":[148,248,292],"by":[149,186],"\u224840%":[150],"large":[152,204],"parts":[153],"world":[156],"during":[157],"past":[159],"2":[160,305,385,429],"decades,":[161],"substantial":[164,380],"part":[165],"decrease":[168],"can":[169],"be":[170],"ascribed":[171],"preventive":[173],"medicine.":[174],"1Cholesterol-lowering":[175],"statin":[176,325],"therapy":[177,201],"reduces":[178],"major":[182],"adverse":[183],"events":[185],"25%":[187],"50%":[189],"individuals":[191],"with":[192,289],"elevated":[193,294],"low-density":[194],"lipoprotein":[195],"standard":[200],"segment":[205],"population":[208],"Western":[211],"world.The":[212],"statins":[215,239],"made":[216],"us":[217],"wonder":[218],"whether":[219],"we":[220],"could":[221],"realistically":[222],"expect":[223],"any":[224,258],"further":[225,232,261],"improvement":[226],"prevention.This":[229],"attitude":[230],"gained":[231],"when":[234],"found":[237],"anti-inflammatory":[242],"properties.Although":[243],"residual":[244],"risk":[245],"after":[246],"remains":[249],"high,":[250],"many":[251],"clinicians":[252],"investigators":[254],"did":[255],"not":[256],"see":[257],"reason":[259],"development":[262],"prevention.The":[265],"study":[270,311,392],"demand":[271],"reassessment":[273],"situation.":[276],"2ANTOS":[277],"randomized,":[280],"double-blind":[281],"secondary":[282],"10":[286],"061":[287],"patients":[288],"prior":[290],"levels":[295],"marker,":[299],"high-sensitive":[300,373],"C-reactive":[301,374],"protein":[302,375],"(>2":[303],"mg/L).":[304],"In":[306],"all,":[307],"80%":[308],"participants":[312],"were":[313,323,327],"treated":[314],"hypertension,":[316],"40%":[317],"had":[318,378],"diabetes":[319],"mellitus,":[320],">90%":[322],"on":[324,382],"therapy.They":[326],"randomized":[328],"into":[329],"4":[330],"groups":[331,422],"received":[333],"canakinumab,":[334],"human":[336],"monoclonal":[337],"antibody":[338,426],"inflammatory":[341],"cytokine,":[342],"interleukin":[343],"(IL)-1\u03b2":[344],"3":[346],"different":[347],"dosages,":[348],"placebo.Canakinumab":[350],"currently":[352],"used":[353],"clinically":[354],"some":[356],"rare":[357],"autoinflammatory":[358],"conditions":[359],"as":[361],"second":[363],"line":[364],"treatment":[366],"rheumatoid":[368],"diseases.As":[369],"expected,":[370],"canakinumab":[371],"reduced":[372,404],"levels;":[376],"no":[379],"effect":[381],"plasma":[383],"lipids.":[384],"The":[386],"primary":[387],"end":[388,406],"point":[389,407],"first":[395],"occurrence":[396],"death.Canakinumab":[403],"significantly,":[408],"from":[409],"4.5":[410],"per":[411,427],"100":[412],"person-years":[413],"placebo":[416],"group":[417],"3.9":[419],"receiving":[423],"\u2265150":[424],"mg":[425],"dose.":[428],"This":[430],"translated":[431],"15%":[434],"relative":[435],"Inflammation":[437],"AtherosclerosisThe":[439],"End":[440],"Controversy":[443]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2754580435","counts_by_year":[{"year":2026,"cited_by_count":11},{"year":2025,"cited_by_count":16},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":19},{"year":2022,"cited_by_count":15},{"year":2021,"cited_by_count":20},{"year":2020,"cited_by_count":18},{"year":2019,"cited_by_count":18},{"year":2018,"cited_by_count":24},{"year":2017,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2017-09-25T00:00:00"}
